Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

145 public trials 32 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Recruiting

Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)

NCT06630104

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Mayo Clinic Health System in Albert Lea Albert Lea, Minnesota, United States
  • Mayo Clinic Health System-Mankato Mankato, Minnesota, United States
View Trial Details
Recruiting

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

NCT05722886

Conditions
Haematological Malignancy, Hematologic Diseases, Hematologic Neoplasms, +9 more
Locations
  • Belfast City Hospital Belfast, United Kingdom
  • University Hospital Birmingham Birmingham, United Kingdom
  • Birmingham Children's Hospital Birmingham, United Kingdom
  • Bristol Royal Hospital for Children Bristol, United Kingdom
View all 27 locations
View Trial Details
Recruiting

Registry of Older Patients With Cancer

NCT01137825

Conditions
Amyloidosis, Blast Crisis, Blood Coagulation Disorders, +98 more
Locations
  • Seby B. Jones Cancer Center Boone, North Carolina, United States
  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill, North Carolina, United States
  • East Carolina University Greenville, North Carolina, United States
  • Pardee Cancer Center Hendersonville, North Carolina, United States
View Trial Details
Recruiting

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

NCT03328078

Conditions
Disease Attributes, Hematologic Diseases, Hematologic Neoplasms, +17 more
Locations
  • St. Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • Mayo Clinic Phoenix, Arizona, United States
  • City of Hope Duarte, California, United States
  • Providence St. John's Health Center Santa Monica, California, United States
View all 45 locations
View Trial Details
Recruiting

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

NCT04329728

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +22 more
Locations
  • City of Hope Duarte, California, United States
  • Los Angeles Cancer Network Los Angeles, California, United States
  • UCLA Medical Center of Hematology/Oncology Los Angeles, California, United States
  • Innovative Clinical Research Institute Whittier, California, United States
View Trial Details

Related conditions